Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

NCI to sponsor clinical trials of Pharmacyclics BTK inhibitor

Aug. 11, 2011

Array BioPharma and Genentech enter agreement for Chk1 program

Aug. 11, 2011

New histone deacetylase 9 inhibitors claimed

Aug. 11, 2011

Novel B-raf inhibitors patented by Selexagen

Aug. 11, 2011

New radioimmunotherapy enters phase I evaluation in HER2-positive intra-abdominal cancers

Aug. 10, 2011

DelMar Pharmaceuticals receives Canada Industrial Research Assistance Program funding

Aug. 10, 2011

U.S. Department of Defense contracts Neuralstem to develop brain tumor therapy

Aug. 10, 2011

Tempero Pharmaceuticals presents novel histone deacetylase 9 inhibitors

Aug. 10, 2011

RNAi screen leads to identification of new target and agent for treatment of AML

Aug. 9, 2011

Phase III study of tivantinib/erlotinib combination begins in NSCLC

Aug. 9, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 22, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 22, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...